We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Polar Capital Global Healthcare Trust plc (PCGH) Ordinary 25p Shares

Sell:388.00p Buy:391.00p 0 Change: 3.00p (0.77%)
FTSE All Share:0.05%
Market closed |  Prices as at close on 4 November 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Tender Offer

Polar Capital Global Healthcare Trust plc Ordinary 25p Shares

Type:
Tender Offer
Shareholder action required:
Yes
Status:
Client deadline
Details (last updated 3 Nov 2025)

Polar Capital Global Healthcare Trust plc is proposing to repurchase up to 100% of its shares in issue. To do this the company is offering to buy its shares at a price to be calculated based on the net asset value (NAV) as of close of business on 27 November 2025, less costs. This is called a tender offer. The tender offer is subject to shareholder approval at a meeting to be held on Thursday 27 November 2025.


The tender offer is also conditional on the satisfaction of the Continuation Conditions, which include the company not being required to purchase via the tender offer more than 40% of the shares in issue. If this Continuation Condition is not satisfied, the tender offer will not proceed and the Board, at its discretion, will announce its intention to put forward proposals for the liquidation of the Company, together with the option of an appropriate rollover vehicle.


You can ask to sell all or part of your holding in the offer. If you don’t want to sell any shares, you don’t need to do anything. If the tender offer does not proceed, we will write to you again with details of the liquidation once they have been announced.


Sell shares in the offer – Act by noon on Monday 24 November 2025


Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter/message and not on the summary information outlined above. 

×
Sell:388.00p
Buy:391.00p
Change: 3.00p (0.77%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 4 November 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Tender Offer

Polar Capital Global Healthcare Trust plc Ordinary 25p Shares

Type:
Tender Offer
Shareholder action required:
Yes
Status:
Client deadline
Details (last updated 3 Nov 2025)

Polar Capital Global Healthcare Trust plc is proposing to repurchase up to 100% of its shares in issue. To do this the company is offering to buy its shares at a price to be calculated based on the net asset value (NAV) as of close of business on 27 November 2025, less costs. This is called a tender offer. The tender offer is subject to shareholder approval at a meeting to be held on Thursday 27 November 2025.


The tender offer is also conditional on the satisfaction of the Continuation Conditions, which include the company not being required to purchase via the tender offer more than 40% of the shares in issue. If this Continuation Condition is not satisfied, the tender offer will not proceed and the Board, at its discretion, will announce its intention to put forward proposals for the liquidation of the Company, together with the option of an appropriate rollover vehicle.


You can ask to sell all or part of your holding in the offer. If you don’t want to sell any shares, you don’t need to do anything. If the tender offer does not proceed, we will write to you again with details of the liquidation once they have been announced.


Sell shares in the offer – Act by noon on Monday 24 November 2025


Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter/message and not on the summary information outlined above. 

×
Sell:388.00p
Buy:391.00p
Change: 3.00p (0.77%)
Market closed |  Prices as at close on 4 November 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Tender Offer

Polar Capital Global Healthcare Trust plc Ordinary 25p Shares

Type:
Tender Offer
Shareholder action required:
Yes
Status:
Client deadline
Details (last updated 3 Nov 2025)

Polar Capital Global Healthcare Trust plc is proposing to repurchase up to 100% of its shares in issue. To do this the company is offering to buy its shares at a price to be calculated based on the net asset value (NAV) as of close of business on 27 November 2025, less costs. This is called a tender offer. The tender offer is subject to shareholder approval at a meeting to be held on Thursday 27 November 2025.


The tender offer is also conditional on the satisfaction of the Continuation Conditions, which include the company not being required to purchase via the tender offer more than 40% of the shares in issue. If this Continuation Condition is not satisfied, the tender offer will not proceed and the Board, at its discretion, will announce its intention to put forward proposals for the liquidation of the Company, together with the option of an appropriate rollover vehicle.


You can ask to sell all or part of your holding in the offer. If you don’t want to sell any shares, you don’t need to do anything. If the tender offer does not proceed, we will write to you again with details of the liquidation once they have been announced.


Sell shares in the offer – Act by noon on Monday 24 November 2025


Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter/message and not on the summary information outlined above. 

×
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Objective

The Company’s investment objective is to generate capital growth by investing in a global portfolio of healthcare stocks.The Company seeks to achieve this objective by investing in a diversified global portfolio consisting primarily of listed equities issued by healthcare companies involved in pharmaceuticals, medical services, medical devices and biotechnology. The portfolio is expected to be diversified by factors such as geography, industry sub-sector and investment size.
Security Weight
Eli Lilly and Co 7.12%
AstraZeneca plc Ordinary US$0.25 6.06%
Abbott Laboratories 4.95%
Ucb SA NPV (CDI) 3.81%
Genmab A/S DKK1 3.59%
Thermo Fisher Scientific Inc 3.44%
Teva Pharmaceutical Industries Ltd ADR 3.30%
Sandoz Group AG CHF0.05 3.29%
Exact Sciences Corp 3.16%
Edwards Lifesciences Corp 3.09%
Sector Weight
Healthcare 98.06%
Country Weight
United States 55.72%
Denmark 13.69%
United Kingdom 6.06%
Switzerland 5.22%
India 4.64%
Belgium 3.81%
Israel 3.30%
Germany 2.84%
Ireland 1.65%
Japan 1.12%

Fee Structure

Management fee is 0.75% p.a. of the lower of the Market Capitalisation and NAV. Performance fee is equal to 10% of the excess total return over benchmark Index plus 1.5% p.a. compounded annually. Agreement terminable not less than 12 months written notice.

Dividend Policy

The Company focus remains on capital growth, and the dividend will be paid bi-annually in February and August. The policy may result in lower dividends being paid than historically to recognise the focus on capital growth.

ASSET SPLIT

Total number of holdings: 40.

Trust Manager

James Douglas

Manager Bio

James joined Polar Capital in September 2015 and is a Fund Manager for the Healthcare team. He was appointed Co-Fund Manager for the Polar Capital Global Healthcare Trust in May 2017.Prior to joining Polar Capital, James worked in equity sales specialising in global healthcare at Morgan Stanley, RBS and HSBC. James also has equity research experience garnered from his time at UBS, where he worked as an analyst in the European pharmaceutical and biotechnology team. Before moving across to the financial sector, he worked as a consultant for EvaluatePharma. James received a PhD and first class honours degree in Medicinal Chemistry from Newcastle University. Further to this, James also holds an ACCA diploma in financial management.

Board Of Directors

Lisa ArnoldChairman, Jeremy Whitley, Neal Ransome, Caroline Gulliver, Stacey Parrinder-Johnson

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.